<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="132">
  <stage>Registered</stage>
  <submitdate>2/11/1999</submitdate>
  <approvaldate>2/11/1999</approvaldate>
  <nctid>NCT00002366</nctid>
  <trial_identification>
    <studytitle>The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma</studytitle>
    <scientifictitle>A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>M95-320</secondaryid>
    <secondaryid>245C</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sarcoma, Kaposi</healthcondition>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ritonavir

Treatment: drugs: Ritonavir


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Patients may receive oral acyclovir and may continue prophylactic treatment for PCP,
             fungal infection, MAC and toxoplasmosis.

          -  Topical treatment and intralesional chemotherapy will be allowed for lesions which
             will not be used as indicator or biopsy lesions.

        Concurrent Treatment:

        Allowed:

        Localized radiotherapy will be allowed for lesions which will not be used as indicator or
        biopsy lesions.

        Patients must have:

          -  Documentation of a positive ELISA test for HIV with a confirmatory test.

          -  Biopsy proven, cutaneous or oropharyngeal Kaposi's sarcoma.

          -  Vital signs, physical examination and laboratory assessments that exhibit no evidence
             of an acute illness.

          -  Patients must agree to report all current medications to the primary investigator and
             obtain prior permission to use them when feasible.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

          -  Evidence of pulmonary Kaposi's sarcoma.

          -  Positive urine screen for recreational drugs.

          -  Current participation in another antiviral research study.

          -  Investigator anticipates poor patient compliance with the protocol.

          -  Patient has any condition that, in the investigator's opinion, may obscure the proper
             observation of the safety or activity of ritonavir.

        Concurrent Medication:

        Excluded:

          -  Antiretroviral therapy.

          -  Protease inhibitor therapy.

          -  Antiviral agent (e.g., oral ganciclovir or Foscarnet) or prophylactic medication for
             an AIDS defining illness which the patient cannot be removed from.

          -  Chemotherapy for Kaposi's sarcoma.

          -  Treatment with any medications that may interact with ritonavir.

        Concurrent Treatment:

        Excluded:

        Radiotherapy for Kaposi's sarcoma.

        Patients with any of the following prior conditions are excluded:

          -  History of psychiatric illness which is currently medically significant.

          -  History of pancreatitis.

        Prior Medication:

        Excluded:

          -  All antiretroviral therapy within 2 weeks prior to the start of the treatment phase of
             the study.

          -  Systemic chemotherapy of interferon within 30 days prior to study entry.

          -  Previous treatment with a protease inhibitor.

        Risk Behavior:

        Excluded:

        Active substance abuse.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Prince Henry's Hosp / Med Oncology - Sydney</hospital>
    <hospital>Saint Vincent's Hosp Med Centre - Sydney</hospital>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002366</trialwebsite>
    <publication>Carr A, Milliken S, Lewis C, Mitsuyasu R, Miles S, Newell M, Cooper DA. A pilot phase II safety and activity study of ritonavir in the treatment of HIV-associated cutaneous Kaposi's sarcoma. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:194 (abstract no 703)
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>